Logo image
The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers
Journal article   Open access

The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers

David C Ishizawar, Karen M Janosko, Jeffrey J Teuteberg, Linda M Cadaret, Michael A Mathier and Dennis M McNamara
Clinical and translational science, Vol.1(2), pp.151-154
09/2008
DOI: 10.1111/j.1752-8062.2008.00020.x
PMCID: PMC5439562
PMID: 20443839
url
https://europepmc.org/articles/pmc5439562View
Published (Version of record) Open Access

Abstract

The role of beta-receptor selectivity for the interaction between the angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and beta-blocker therapy was investigated in 479 subjects with left ventricular dysfunction. Subjects were separated into no beta-blocker, beta1 -selective, and nonselective beta-blocker treatment groups. The D allele adversely affected transplant-free survival for subjects not on beta-blockers (p= 0.004). Treatment with selective beta1-blockers eliminated the impact of the D allele (p= 0.51) in a manner similar to nonselective beta1,2-blockers (p= 0.80). Treatment with beta1-blockers was sufficient to eliminate the adverse impact of the ACE D allele, suggesting this pharmacogenetic interaction is mediated through the beta1-receptor.
Adrenergic beta-Antagonists - classification Pharmacogenetics Demography Humans Middle Aged Genotype INDEL Mutation - genetics Male Receptors, Adrenergic, beta-1 - metabolism Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists - pharmacology Disease-Free Survival Peptidyl-Dipeptidase A - genetics Alleles Female Cohort Studies

Details

Metrics

9 Record Views
Logo image